Incyte Corp SEC Filings

Edmund Harrigan, a director of Incyte Corp (INCY), acquired 289 shares of common stock on 09/30/2025 at a price of $84.81 per share. The shares were issued as restricted shares under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of a quarterly director retainer, and the filing states the restricted shares are fully vested. After this transaction, the reporting person beneficially owns 20,608 shares, which includes 2,518 shares issuable under previously reported restricted stock units that have not vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Form 144 notice for INCY (Incyte Corp): An individual, Sheila Denton, filed a proposed sale of 599 common shares to be executed through Morgan Stanley Smith Barney LLC on 10/02/2025 on the NASDAQ. The filing shows those 599 shares were acquired on 10/02/2025 by exercising stock options and paid in cash. The form lists six prior open-market sales by the same person during Jul–Sep 2025 totaling 6,165 shares sold across multiple dates with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information.

Incyte Corp (INCY) reported equity awards to David H. Gardner, EVP and Chief Strategy Officer, on 09/22/2025. The filing shows a grant of 9,429 restricted stock units (RSUs) that vest 25% annually over four years and are settled one-for-one in common stock. The report also lists 23,573 performance shares that can pay up to 200% of one share based on relative total shareholder return versus a fixed peer group over a three-year performance period beginning 01/01/2025, with earned shares vesting on the third anniversary. Additionally, 42,899 employee stock options were granted at an $84.73 exercise price, exercisable in 37 installments with the first 25% after one year and monthly vesting thereafter, expiring 09/22/2035. The filing shows the reporting person beneficially owned 9,429 common shares and had derivative interests underlying 23,573 performance shares and 42,899 options following the grants.

Incyte Corp (INCY) Form 3 filed for David H. Gardner. The filing, reporting an event dated 09/22/2025, shows Mr. Gardner identified as an EVP, Chief Strategy Officer and officer/director of the issuer. The report states no securities are beneficially owned by the reporting person as of the event date. The form is signed by an attorney-in-fact on 09/24/2025.

Form 144 filing for INCY by named seller Barry Flannelly. The filer notifies a proposed sale of 17,447 common shares valued at $1,487,531.22 to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/18/2025. The shares were acquired on 09/18/2025 by stock option exercise from the issuer and payment was made in cash the same day. The filing also lists five prior Common share sales by Barry Flannelly during July–August 2025 totaling 101,435 shares for gross proceeds of $8,631,432.53. The notice includes the required attestation about possession of material non-public information.

Form 144 filing for INCY by named seller Barry Flannelly. The filer notifies a proposed sale of 17,447 common shares valued at $1,487,531.22 to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/18/2025. The shares were acquired on 09/18/2025 by stock option exercise from the issuer and payment was made in cash the same day. The filing also lists five prior Common share sales by Barry Flannelly during July–August 2025 totaling 101,435 shares for gross proceeds of $8,631,432.53. The notice includes the required attestation about possession of material non-public information.

Sheila A. Denton, EVP & General Counsel of Incyte Corporation (INCY), reported multiple transactions on 09/16/2025. The Form 4 shows a non-derivative acquisition of 278 shares of common stock at $64.25 and a non-derivative disposition of 278 shares at $83.15, leaving her with 33,200 shares beneficially owned after the sale. The filing also reports exercise of 278 employee stock options with a $64.25 exercise price, resulting in 278 underlying shares and total derivative holdings of 9,438 option-related shares exercisable through 07/14/2034. The filing discloses that 32,544 of the reported common shares are issuable under previously reported restricted stock units and earned performance units that have not vested.

Sheila A. Denton, EVP & General Counsel of Incyte Corporation (INCY), reported multiple transactions on 09/16/2025. The Form 4 shows a non-derivative acquisition of 278 shares of common stock at $64.25 and a non-derivative disposition of 278 shares at $83.15, leaving her with 33,200 shares beneficially owned after the sale. The filing also reports exercise of 278 employee stock options with a $64.25 exercise price, resulting in 278 underlying shares and total derivative holdings of 9,438 option-related shares exercisable through 07/14/2034. The filing discloses that 32,544 of the reported common shares are issuable under previously reported restricted stock units and earned performance units that have not vested.

Form 144 filing for Incyte Corp (INCY) discloses a proposed sale of 278 common shares by an insider through Morgan Stanley Smith Barney on 09/16/2025 with an aggregate market value of $23,115.70 and total shares outstanding listed as 195,276,145. The shares were acquired and paid for on 09/16/2025 via a stock option exercise with cash payment. The filer also reported six prior sales by the same person between 07/02/2025 and 09/02/2025, totaling 6,187 shares and gross proceeds shown for each trade.

Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), reported insider transactions dated 09/02/2025. She exercised an employee stock option to acquire 598 shares at an exercise price of $58.06 and simultaneously sold 598 shares at $84.97. The Form 4 shows beneficial ownership amounts of 33,798 and 33,200 shares following the reported transactions, and notes that 32,544 shares are issuable from previously reported restricted stock units and performance units that have not vested. The filing indicates the transaction was made pursuant to a written plan consistent with Rule 10b5-1 and was signed on 09/04/2025 by an attorney-in-fact.

Form 144 notice for Incyte Genomics Inc (INCY): The filer reported a proposed sale of 598 common shares via Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $50,812.06 and an approximate sale date of 09/02/2025. The shares were acquired the same day, 09/02/2025, by stock option exercise from the issuer and paid for in cash. The filer also disclosed six prior sales in the past three months totaling 7,384 shares for gross proceeds of $490,810.62 across dates from 06/03/2025 to 08/15/2025. The filer attests they are not aware of any undisclosed material adverse information.